Company: SHPH
Filing Date: 2025-08-05
Form Type: S-1
Source: 0001641172-25-022101
Chunk: 6

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-08-05
Form: S-1
Chunk 6
---
 within the deadline required under the registration rights agreement and its failure to do so within such deadline was due to a request by the investor. The Company has interpreted such request by the investor as a waiver of any liquidated damages under the registration rights agreement with respect to the Company’s failure to file the registration statement within 10 days of the closing date.

WestPark Capital, Inc. (“WestPark”) acted as the placement agent in connection with the private placement pursuant to an engagement agreement between the Company and WestPark, as amended (as amended, the “Engagement Agreement”). Pursuant to the Engagement Agreement, the Company paid WestPark a fee of 4% of the gross proceeds received by the Company in the private placement. The Company also reimbursed certain expenses of WestPark.

This prospectus covers the resale of the 21,924 shares and 1,158,953 shares issuable upon exercise of the pre-funded warrants issued under the purchase agreement.

| 5 |

<div align='center'>RISK FACTORS</div>

An investment in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks and uncertainties discussed below, as well as those under the heading “Risk Factors” contained in our most recent annual report on Form 10-K filed with the SEC, and as incorporated by reference in this prospectus, as the same may be amended, supplemented or superseded by the risks and uncertainties described under similar headings in the other documents that are filed by us after the date hereof and incorporated by reference into this prospectus. Please also read carefully the section below titled “Cautionary Note Regarding Forward-Looking Statements.”

The sale of a substantial amount of our common stock, including resale of the shares of common stock by the selling stockholder in the public market, could adversely affect the market price of our common stock.

We are registering for resale 1,180,877 shares of common stock, including 1,158,953 shares issuable upon the exercise of pre-funded warrants held by the selling stockholder. Sales of substantial amounts of our common stock in the public market, or the perception that such sales might occur, could adversely affect the market price of our common stock. We cannot predict if and when the selling stockholder may sell such shares in the public market.

<div align='center'>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

All statements in this prospectus and the documents incorporated by reference that are not historical facts should